Prof Sherene Loi
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
756 Scholarly works
42 Projects
HIGHLIGHTS
2026
Journal article
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.
DOI: 10.1016/j.annonc.2026.05.7072026
Journal article
Giredestrant (GIRE) palbociclib (PALBO) vs letrozole (LET) PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER , HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.
DOI: 10.1200/jco.2026.44.17_suppl.lba10062026
Research grants (ARC, NHMRC, MRFF)
Innovating in Breast Cancer Immunology Treatment and Prevention
2022
Journal article
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
DOI: 10.1038/s43018-022-00413-x2021
Journal article
Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
DOI: 10.1093/jnci/djab1112018
Research Grant
Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
2018
Research grants (other domestic)
2018 NBCF Endowed Chair Program
RECENT SCHOLARLY WORKS
2026
Journal article
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1 metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.
DOI: 10.1200/jco.2026.44.17_suppl.lba10002026
Journal article
ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) pembrolizumab (pembro) vs chemotherapy (chemo) pembro in participants (pts) with previously untreated PD-L1 metastatic triple-negative breast cancer (mTNBC).
DOI: 10.1200/jco.2026.44.16_suppl.10132026
Journal article
Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.
DOI: 10.1200/jco.2026.44.16_suppl.5542026
Journal article
Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER , HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
DOI: 10.1200/jco.2026.44.16_suppl.5022026
Journal article
Trastuzumab deruxtecan (T-DXd) durvalumab (D) in patients (pts) with previously untreated HER2 unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.
DOI: 10.1200/JCO.2026.44.16_suppl.10122026
Journal article
Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) nonsteroidal aromatase inhibitor (NSAI) in HR /HER2− early breast cancer (EBC).
DOI: 10.1200/jco.2026.44.16_suppl.5012026
Journal article
Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR ), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) palbociclib (PALBO) fulvestrant (FULV).
DOI: 10.1200/jco.2026.44.16_suppl.10792026
Journal article
ReDiscover-2, a phase 3 study of zovegalisib (zovega, RLY-2608) fulvestrant (fulv) versus capivasertib (capi) fulv as treatment for locally advanced or metastatic PIK3CA -mutant HR / HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
DOI: 10.1200/jco.2026.44.16_suppl.tps1148